Clinical Trial Update: A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults [Phase 1]

View source ↗

Summary

Phase 1 long-term follow-up study of an investigational vaccine in adults assessing immunogenicity and safety up to 4 years; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Disorders

Drugs mentioned

• Investigational vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Disorders | Phase 1 | Status: COMPLETED | Results posted: 2021-04-08